Anavex Withdraws EU Marketing Application for Alzheimer's Therapy

miércoles, 25 de marzo de 2026, 1:18 pm ET1 min de lectura
AVXL--

Anavex Life Sciences (AVXL) stock dropped 18% in premarket trading after the company withdrew its marketing authorization application for Alzheimer's therapy candidate blarcamesine due to regulatory feedback from the EU drug regulator. The decision was made after the regulator provided feedback on the application.

Anavex Withdraws EU Marketing Application for Alzheimer's Therapy

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios